Astrazeneca Regulatory News (AZN)

9 November 2016 07:00

CHANGE TO ASTRAZENECA BOARD OF DIRECTORS

AstraZeneca today announced that Jean-Philippe Courtois, a Non-Executive Director, will step down from the Board of AstraZeneca PLC and as a member of the Company's Audit Committee with effect from 1 December 2016.

Mr Courtois was appointed as a Non-Executive Director of AstraZeneca in 2008. The Board's Nomination and Governance Committee started succession planning work in February this year, in anticipation of him reaching nine years' tenure in 2017. Mr Courtois has recently taken on new responsibilities as Executive Vice President and President, Microsoft Global Sales, Marketing and Operations.

Leif Johansson, AstraZeneca Chairman, said: "On behalf of the Board, I would like to express my gratitude for Jean-Philippe's contribution to our work and that of the Audit Committee. I speak for all my colleagues in saying that we will miss his business acumen, extensive experience of the global technology industry, common sense and collegiality. We wish him all the best for his future endeavours."

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.

Adrian Kemp

Company Secretary, AstraZeneca PLC

-ENDS-